Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution

Journal of Immunotherapy

Volumn 24, Issue 1, 2001, Pages 1-9

  Bownds, S ^a   Tong On, P ^a   Rosenberg, S A ^a   Parkhurst, M ^a  

^a NONE   (United States)

Author keywords

Cancer testis antigens; Cytotoxic T lymphocytes; Epitope; HLA A2.1; Immunotherapy; NY ESO 1

Indexed keywords

HLA A2 ANTIGEN; TUMOR ANTIGEN; TUMOR ANTIGEN NY ESO 1; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MELANOMA; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; HLA-A2 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; MELANOMA; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEINS; SOLUTIONS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0035138326     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200101000-00001     Document Type: Article

References (22)

1. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
2. Expression and clinical relevance of NY-ESO-1, MAGE-I and MAGE-3 in neuroblastoma
3. Monitoring CD8 T cell responses to NY-ESO-I: Correlation of humoral and cellular immune responses
4. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes
5. Humoral immune responses of cancer patients against 'cancer-testis' antigen NY-ESO-1: Correlation with clinical events
6. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens
7. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma
8. A breast and melanomashared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames
9. Identification of CD4+ T Cell Epitopes from NY-ESO-1 Presented by HLA-DR Molecules
10. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL
11. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas
12. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids
13. Development of a retro-virus-based complementary DNA expression system for the cloning of tumor antigens
14. MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte
15. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2)
16. MHC ligands and peptide motifs: First listing
17. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules
18. Identification of the genes encoding cancer antigens: Implications for cancer immunotherapy
19. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
20. Cancer-testis antigens: Targets for cancer immunotherapy
21. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gpl00 modified at HLA-A*0201-binding residues
22. Changes in the Fine Specificity of gpl00(209-217)-reactive T cells in patients after vaccination with a peptide modified at an HLA-A2.1 anchor residue